CLLS

Cellectis SA

3.95 0.19 (5.05%)

Delayed Prices By NASDAQ, in USD Market Closed

Trade

3.94

3.99

Overview

Prev Close3.95

Day's Range 3.71 - 3.98

52 Week Range 2.85 - 16.49

Average Volume (3m)223.55K

1-Year Return-75.76%

Beta1.3588

Market Cap180.99M

P/E Ratio

Revenue33.39M

EPS-2.952

Dividend (Yield) (0%)

1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max

Chart times in UTC

Sector
Health Technology

Industry Pharmaceuticals Major

CEO André Choulika, PhD

Employees 294

FINANCIAL SUMMARY

For the quarter ended 31/3/2022, Cellectis SA's revenues decreased by 86.10% and amounted to 1.70M. Net income decreased by 23.78% to -34.76M. Net assets decreased by 14.13% to 203.05M and EPS decreased from -0.55 to -0.70.

CLLS's Investor Relations

Income StatementBalance SheetCash Flow Statement

Quarterly

3.63%

-398.74%

-471.62%

-28.63%

06/21

09/21

12/21

03/22

11.16M

8.31M

12.21M

1.7M

-577.28K

-901K

6.6M

-3.91M

-41.02M

N/A

-32.38M

-37.45M

-41.56M

-40.07M

-28.08M

-34.76M